Flagship Pioneering merges three portfolio companies to boost AI drug discovery

Flagship Pioneering, a biotech incubator based in Cambridge, Massachusetts, announced it is merging three of its portfolio companies into a single organization.

The consolidation includes a company that has been part of the Flagship network for about ten years, and is intended to create a stronger platform for artificial-intelligence driven drug discovery.

By uniting the teams and technologies, Flagship hopes to better compete in the rapidly expanding AI drug-discovery market and accelerate the development of new therapeutics.